RE:%s of the optimized group @450-days: 43.7% CR and 64.4% TR SF, no need to speculate about the results of the non-optimized/undertreated cohort: they can be derived from the MD&A dated 28 April 2022, page 5.
To get them, first deduct the Phase Ib results (2 CRs and 1 NR) from the upper table. This will give you the results for Phase II alone.
Next, from these Phase II-alone results, deduct the results presented for the Phase II Optimized cohort (the lower table). This will give you the results for the Phase II undertreated cohort alone.
If my method is sound, this produces for the undertreated cohort alone 4CRs and 2PRs at 90 days, and 2CRs and 1 PR at 450 days.
Assuming that the results for the undertreated cohort have not been adjusted after 28/4/2022 (not necessarily true), they can also be used to calculate the results for the optimized cohort alone on later dates.
All to my best knowledge/interpretation, DYOR.